Therapeutic options to reduce advanced glycation end products in patients with diabetes mellitus: A review

Diabetes Res Clin Pract. 2019 Feb:148:54-63. doi: 10.1016/j.diabres.2018.11.016. Epub 2018 Nov 27.

Abstract

Diabetes mellitus (DM) defines metabolic disorders, characterised by elevated levels of blood glucose. Chronic hyperglycaemic state promotes consequently the formation of advanced glycation end products (AGEs) and the expression of their receptor (RAGE) which aggravate many diabetic complications. Due to the relevant role of AGEs and RAGE, several therapeutic approaches with an anti-AGE or RAGE-antagonizing effect are investigated. These therapeutic options include AGE cross-link breakers, AGE inhibitors, RAGE antagonists, drugs clinically approved for various indications like antidiabetic, antihypertensive drugs or statins, as well as dietary and phytotherapeutic approaches. The aim of this review is to give an overview of these therapeutic approaches, their outcomes in clinical studies and their role in the management of diabetes and its complications.

Keywords: AGE cross-link breaker; AGE inhibitors; Advanced glycation end products; Diabetes mellitus; RAGE antagonists.

Publication types

  • Review

MeSH terms

  • Animals
  • Antihypertensive Agents / therapeutic use
  • Blood Glucose / metabolism
  • Diabetes Mellitus / metabolism*
  • Diabetes Mellitus / therapy*
  • Diet / methods
  • Diet Therapy / methods
  • Glycation End Products, Advanced / adverse effects
  • Glycation End Products, Advanced / antagonists & inhibitors
  • Glycation End Products, Advanced / metabolism*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypoglycemic Agents / classification
  • Hypoglycemic Agents / therapeutic use

Substances

  • Antihypertensive Agents
  • Blood Glucose
  • Glycation End Products, Advanced
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypoglycemic Agents